» Articles » PMID: 38734900

Prophylactic Vaccination Inducing Anti-Env Antibodies Can Result in Protection Against HTLV-1 Challenge in Macaques

Abstract

Human T cell leukemia/T-lymphotropic virus type 1 (HTLV-1) infection occurs by cell-to-cell transmission and can induce fatal adult T cell leukemia. Vaccine development is critical for the control of HTLV-1 transmission. However, determining whether vaccine-induced anti-Env antibodies can prevent cell-to-cell HTLV-1 transmission is challenging. Here, we examined the protective efficacy of a vaccine inducing anti-Env antibodies against HTLV-1 challenge in cynomolgus macaques. Eight of 10 vaccinated macaques produced anti-HTLV-1 neutralizing antibodies (NAbs) and were protected from an intravenous challenge with 10 HTLV-1-producing cells. In contrast, the 2 vaccinated macaques without NAb induction and 10 unvaccinated controls showed HTLV-1 infection with detectable proviral load after challenge. Five of the eight protected macaques were administered with an anti-CD8 monoclonal antibody, but proviruses remained undetectable and no increase in anti-HTLV-1 antibodies was observed even after CD8 cell depletion in three of them. Analysis of Env-specific T cell responses did not suggest involvement of vaccine-induced Env-specific T cell responses in the protection. These results indicate that anti-Env antibody induction by vaccination can result in functionally sterile HTLV-1 protection, implying the rationale for strategies aimed at anti-Env antibody induction in prophylactic HTLV-1 vaccine development.

Citing Articles

A promising advance in blocking HTLV-1 transmission: Addressing a global public health problem.

Vallinoto A Mol Ther. 2024; 32(7):2050-2051.

PMID: 38908379 PMC: 11286807. DOI: 10.1016/j.ymthe.2024.06.010.

References
1.
Akari H, Suzuki T, Ikeda K, Hoshino H, Tomono T, Murotsuka T . Prophylaxis of experimental HTLV-I infection in cynomolgus monkeys by passive immunization. Vaccine. 1997; 15(12-13):1391-5. DOI: 10.1016/s0264-410x(97)00055-8. View

2.
Miyakoshi H, Koide H, Aoki T . In vitro antibody-dependent cellular cytotoxicity against human T-cell leukemia/lymphoma virus (HTLV)-producing cells. Int J Cancer. 1984; 33(3):287-91. DOI: 10.1002/ijc.2910330302. View

3.
Kano M, Matano T, Kato A, Nakamura H, Takeda A, Suzaki Y . Primary replication of a recombinant Sendai virus vector in macaques. J Gen Virol. 2002; 83(Pt 6):1377-1386. DOI: 10.1099/0022-1317-83-6-1377. View

4.
Takeda A, Igarashi H, Kawada M, Tsukamoto T, Yamamoto H, Inoue M . Evaluation of the immunogenicity of replication-competent V-knocked-out and replication-defective F-deleted Sendai virus vector-based vaccines in macaques. Vaccine. 2008; 26(52):6839-43. DOI: 10.1016/j.vaccine.2008.09.074. View

5.
Tanaka Y, Tanaka R, Terada E, Koyanagi Y, Miyano-Kurosaki N, Yamamoto N . Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization. J Virol. 1994; 68(10):6323-31. PMC: 237053. DOI: 10.1128/JVI.68.10.6323-6331.1994. View